Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine (U300)
Device: MyStar DoseCoach

First Posted Date: 2015-10-23

Last Posted Date: 2016-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 151

Registration Number: NCT02585674

Locations: 🇬🇧
Investigational Site Number 826010, Londonderry, United Kingdom
🇬🇧
Investigational Site Number 826006, Dumfries, United Kingdom
🇬🇧
Investigational Site Number 826008, East Kilbride, United Kingdom

and more 16 locations

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Placebo
Drug: Alirocumab
Drug: Non-statin Lipid-Modifying Therapy
Drug: Atorvastatin
Other: Diet Alone

First Posted Date: 2015-10-22

Last Posted Date: 2019-01-23

Lead Sponsor: Sanofi

Target Recruit Count: 163

Registration Number: NCT02584504

Locations: 🇯🇵
Investigational Site Number 392004, Kawanishi-Shi, Japan
🇯🇵
Investigational Site Number 392016, Shinagawa-Ku, Japan
🇯🇵
Investigational Site Number 392029, Chuo-Ku, Japan

and more 27 locations

A Study of SAR428926 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasm Malignant

Interventions: Drug: SAR428926

First Posted Date: 2015-10-15

Last Posted Date: 2018-08-22

Lead Sponsor: Sanofi

Target Recruit Count: 34

Registration Number: NCT02575781

Locations: 🇩🇰
Investigational Site Number 2080001, København Ø, Denmark
🇪🇸
Investigational Site Number 7240001, Barcelona, Spain
🇫🇷
Investigational Site Number 2500001, Villejuif Cedex, France

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Dupilumab SAR231893/REGN668
Drug: fluticasone propionate and salmeterol
Drug: budesonide and formoterol
Drug: mometasone furoate and formoterol

First Posted Date: 2015-10-09

Last Posted Date: 2022-04-04

Lead Sponsor: Sanofi

Target Recruit Count: 42

Registration Number: NCT02573233

Locations: 🇨🇦
Investigational Site Number 124012, Montreal, Canada
🇺🇸
Investigational Site Number 840028, Pittsburgh, Pennsylvania, United States
🇸🇪
Investigational Site Number 752001, Lund, Sweden

and more 13 locations

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: INSULIN GLARGINE

First Posted Date: 2015-09-10

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 947

Registration Number: NCT02545842

Locations: 🇨🇳
Investigational Site Number 156020, Nanchang, China
🇨🇳
Investigational Site Number 156053, Anshan, China
🇨🇳
Investigational Site Number 156001, Beijing, China

and more 41 locations

A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

Phase 1

Completed

Conditions: Gaucher Disease

Interventions: Drug: eliglustat

First Posted Date: 2015-09-01

Last Posted Date: 2017-03-08

Lead Sponsor: Sanofi

Target Recruit Count: 32

Registration Number: NCT02536937

Locations: 🇺🇸
Investigational Site Number 840004, Miami, Florida, United States
🇺🇸
Investigational Site Number 840001, Knoxville, Tennessee, United States
🇺🇸
Investigational Site Number 840002, St. Paul, Minnesota, United States

28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

Phase 1

Completed

Conditions: Open Angle Glaucoma -Ocular Hypertension

Interventions: Drug: SAR366234
Drug: Latanoprost

First Posted Date: 2015-08-24

Last Posted Date: 2016-04-27

Lead Sponsor: Sanofi

Target Recruit Count: 54

Registration Number: NCT02531152

Locations: 🇺🇸
Investigational Site Number 840001, Inglewood, California, United States
🇺🇸
Investigational Site Number 840005, Roswell, Georgia, United States
🇺🇸
Investigational Site Number 840004, St Joseph, Michigan, United States

and more 2 locations

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Dupilumab
Drug: Oral corticosteroid therapy (prednisone/prednisolone)
Drug: Inhaled corticosteroid (ICS) therapy
Drug: Albuterol/Salbutamol
Drug: Levalbuterol/Levosalbutamol

First Posted Date: 2015-08-19

Last Posted Date: 2019-10-01

Lead Sponsor: Sanofi

Target Recruit Count: 210

Registration Number: NCT02528214

Locations: 🇪🇸
Investigational Site Number 724014, Barcelona, Spain
🇪🇸
Investigational Site Number 724006, Pozuelo De Alarcón, Spain
🇦🇷
Investigational Site Number 032001, Caba, Argentina

and more 77 locations